Table 2.
Pharmacokinetic data.
| Patient | Nilotinib csf concentration [ng/mL], (range) | Nilotinib plasma concentration [ng/mL], (range) | Nilotinib csf/plasma ratio [%], (range) | Csf protein concentration [g/L] | Plasma protein concentration [g/L] | Free nilotinib in plasma concentration [ng/mL]∗ | Nilotinib csf concentration/free nilotinib plasma concentration [%,]∗ |
|---|---|---|---|---|---|---|---|
| 1 | 4 (3.6–15) | 1640 (1544–1736) | 0.26 (0.23–0.84) | 0.49 (0.31–0.75) | 76 (69–77) | 32.8 | 12 |
| 2 | 13 (4–18) | 955 (734–1176) | 0.83 (0.54–1.52) | 0.40 (0.34–0.89) | 65 (56–69) | 19.1 | 68 |
| 3 | 7 (6–9) | 1159 (1082–1237) | 0.63 (0.5–0.79) | 0.50 (0.28–0.67) | 59 (56–67) | 23.2 | 30 |
| 4 | 2.7 (1.5–4.8) | 682 (430–1034) | 0.42 (0.26–0.58) | 0.23 (0.19–0.31) | 71 (62–78) | 13.6 | 20 |
All values are given as median.
∗Unbound (=free) nilotinib concentration calculated by using published nilotinib protein binding of 98%.